Food Ingredients M&A and Valuation Multiples in Q2 2026

"Ingredients" is not one sector — it is a ladder, and the rungs are further apart than almost anywhere in food. At the top, a maker of patented enzymes or specified flavours trades at 20x EBITDA because its product is written into the customer's recipe and cannot easily be swapped out. At the bottom, a starch or sweetener processor trades at 6x because its product is a commodity priced off corn. Across 14 listed names the median sits at 12.2x EV/EBITDA 2026E — but that midpoint describes almost none of them. What determines the multiple is a single question: how hard is the ingredient to replace?

The backdrop: portfolios are being taken apart, not bolted together

The defining feature of the ingredients market in 2026 is not consolidation — it is simplification. The majors are dismantling the conglomerate model they spent two decades building, selling whole divisions to private equity and redeploying the proceeds into buybacks and their highest-value platforms. IFF agreed to sell its Food Ingredients business to CVC for $4.3bn and earlier sold Pharma Solutions to Roquette for $2.85bn; dsm-firmenich is exiting Animal Nutrition & Health entirely, to CVC, having already sold its Feed Enzymes stake to Novonesis; Kerry has become a pure-play taste and nutrition business after exiting dairy and meats; Symrise continues to prune non-core lines. Each transaction produces the same outcome: a leaner, sharper, higher-margin business, and a pool of carved-out assets that private equity is happy to own at single-digit multiples.

Strategic acquirers are paying premium prices, but only for assets that deepen a specified, IP-rich position — natural extracts, cultures, bioactives, formulation capability. Everything else is being valued on cash flow and cost, and increasingly bought by financial sponsors running a buy-and-build playbook. The spread in the listed comparables below is the same spread that determines which of those two conversations an owner ends up in.

What the comparables say

The table below shows median EV/EBITDA 2026E by bucket, alongside the operating metrics that drive those multiples. The ranking tracks switching cost and IP intensity almost perfectly — the more specified and patent-protected the product, the higher the multiple, almost regardless of headline margin.

Food Ingredients — Median EV/EBITDA 2026E by Bucket

Median multiple shown as a horizontal bar, alongside the operating metrics that drive the ranking.

Flavours, fragrances & cultures — the premium tier

The highest-rated corner of ingredients, and the clearest illustration of the thesis. Givaudan (~19.6x), Sensient (~17.8x) and Novonesis (~16.8x) anchor the top because they sell the most defensible products in the entire food chain: patented enzymes, cultures and specified flavours that are formulated into a customer's product, validated, and then almost never changed. Switching costs are enormous, revenue is recurring, and the IP is genuine. Novonesis stands out on quality even at a slightly lower multiple, pairing a sector-leading ~37% EBITDA margin with the fastest growth in the bucket. Symrise (~12.6x), IFF (~11.7x) and Robertet (~10.7x) sit lower on scale, mix and, in IFF's case, the overhang of an ongoing break-up. DSM-Firmenich (~13.0x) screens mid-pack as a group still completing its transition to a pure consumer-nutrition business. Even within the premium tier, the market pays up for the cleanest, most specified portfolios.

Flavours, Fragrances & Cultures — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency.

Specialty & nutrition — the formulated middle

A median of 12.4x for the businesses that sell health, function and formulation rather than pure flavour or pure commodity — a bucket that now rivals flavours, reflecting how strongly the market rewards the "better-for-you" theme. Balchem (~18.6x) is the standout, the highest-rated name in the entire set, rewarded for high-margin encapsulation and human-nutrition actives. Glanbia (~13.0x) has re-rated sharply as its performance-nutrition and actives mix is recognised, while Kerry (~11.9x) sits just below as a scaled taste-and-nutrition solutions house. Corbion (~7.2x) trades down near commodity levels on its preservation-and-lactic-acid base, despite a high-value algae-omega-3 franchise on top. This is the bucket where the equity story is everything: a specified, clinically-backed actives business is valued like flavours, while a more functional, commoditised one drifts toward carbohydrate multiples.

Specialty & Nutrition — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency.

Commodity & carbohydrate — the processing floor

A median of 6.1x, the bottom of the ladder. Ingredion (~5.9x) and Tate & Lyle (~6.1x) are priced as what they largely are: processors of starches, sweeteners and bulk ingredients, exposed to crop costs and offering limited switching costs. ADM (~10.0x) screens higher, but on scale, trading and an agribusiness footprint rather than ingredient specification. Tate & Lyle is the interesting case — its post-CP Kelco reshaping toward specialty texturants and sweeteners is an explicit attempt to climb the ladder out of this bucket, and the market will re-rate it only as that mix shift proves through. These are not poor businesses; they are capital-intensive, cyclical and commoditised, and valued accordingly.

Commodity & Carbohydrate — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency.

Source: company filings / consensus estimates, refreshed June 2026. Shaded cells are at or above the peer-set median.

The same ladder, priced by buyers

The transactions of the last two years map onto the same ladder — and, unusually for a sector note, the most important deals are disposals rather than acquisitions. The disclosed multiples span the full ladder — from 7x for commoditised animal-nutrition assets to ~20x for specified flavour, enzyme and functional-health businesses, with a median around 16x — and where an asset sits on the specification ladder is what determines which end it lands.

The headline activity is the PE-led carve-out of non-core divisions. IFF sold its Food Ingredients business to CVC for $4.3bn at roughly 10x EBITDA, and previously sold Pharma Solutions to Roquette for $2.85bn at around 13x — the higher multiple reflecting the more specified, pharma-grade nature of the excipients business. dsm-firmenich agreed to sell Animal Nutrition & Health to CVC at about 7x standalone (10x including the earlier €1.5bn Feed Enzymes sale to Novonesis) — a lower multiple befitting a more commoditised, volatile animal-feed portfolio. The pattern is consistent: the more specified the asset, the higher the exit multiple, even within the same vendor. At the commodity end, consolidation is now active too: in June 2026 Ingredion agreed to acquire Tate & Lyle for £2.7bn at 9.5x — scale economics in starches and sweeteners, a very different logic from the premium paid for specified assets.

Alongside the mega-carve-outs, strategic and sponsor buy-and-build continues at the specialty end. Givaudan, Kerry and Symrise keep acquiring natural-extract, bioactive and taste-solution businesses to deepen their highest-value platforms — its acquisition of Frulact built a platform past €1bn of revenue. And the most specified assets still command the richest prices: IFF's landmark Frutarom acquisition cleared ~20x EBITDA, and the recent Novonesis purchase of dsm-firmenich's Feed Enzymes business went at ~21x — a reminder of what scarcity, IP and switching costs are worth when a strategic wants them.

For owners, the read-through is the clearest of any food subsector: your exit multiple is set by how specified, protected and hard-to-replace your product is. A clinically-backed actives or cultures business attracts strategic competition at a premium; a commoditised processing business attracts financial buyers at a cash-flow multiple.

Precedent transactions

Food Ingredients M&A — Recent Precedents

¹ 16.0x including $5m contingent on performance.

² 7.0x standalone on normalised EBITDA; ~10x including the prior €1.5bn Feed Enzymes sale to Novonesis, on combined ANH enterprise value of ~€3.7bn.

Source: company announcements and SEC filings, sector press. Headline EV/EBITDA at announcement where disclosed; EBITDA margin is the target's where reported. Not strictly comparable. Illustrative — does not constitute advice.

What this means if you are considering a sale

Your bucket sets the starting line, not the outcome. The 6x-to-20x spread on the screen is the same spread a private buyer will pay between a commoditised carbohydrate processor and a specified, IP-protected actives business. Listed multiples are the floor for the conversation, not the answer. A proper valuation starts by establishing where the business sits on the specification ladder — and building the evidence for why a buyer should pay above the quoted peer set.

Specification rather than scale drives the premium. A patented, formulated, clinically-supported or regulatory-approved ingredient that is hard to substitute commands a far higher multiple than a commoditised input, even at the same margin. Proprietary formulations, blue-chip customer relationships, regulatory approvals and a documented switching cost are the attributes that move a business up the valuation ladder — and they should be the centre of how the business is presented to buyers.

Both buyer pools are unusually active. Strategics are paying premium prices for assets that deepen their highest-value platforms, and private equity is mopping up the carve-outs the majors are releasing. A well-run process can engage both — strategic competition at the top of the ladder, sponsor buy-and-build appetite below it.

Frequently asked questions about food ingredients valuation multiples

What multiple do food ingredients companies sell for?

There is no single number. Across 14 listed food-ingredients companies the median is around 12x EV/EBITDA 2026E, but the range runs from roughly 6x for commodity starch and sweetener processors to nearly 20x for specified flavour, fragrance and enzyme businesses. Private transactions in 2024–26 have cleared anywhere from 7x for commoditised animal-nutrition assets to over 20x for specified natural-ingredient platforms. Where a business sits in that range is driven mainly by how hard its product is to replace once designed into a customer's formulation.

Why do flavour and enzyme companies trade at higher multiples than commodity ingredients?

Because their products are specified, formulated into a customer's recipe, validated and then almost never changed. That creates high switching costs, recurring revenue and genuine intellectual property — the attributes the market rewards. A commodity starch or sweetener, by contrast, is priced off the underlying crop and can be swapped between suppliers, so it earns a far lower multiple even at a similar profit margin.

Who is buying food ingredients businesses in 2026?

Two distinct buyer pools. Strategic acquirers — the large flavour, taste and nutrition houses — pay premium prices for assets that deepen a specified, IP-rich position. At the same time, private equity is unusually active, acquiring the divisions that the majors are carving out as they simplify their portfolios; CVC's purchases of IFF's Food Ingredients business and dsm-firmenich's Animal Nutrition arm are recent examples. For an owner, that means a well-run process can engage both a strategic premium and a sponsor's buy-and-build appetite.

Is now a good time to sell a food ingredients business?

M&A activity is high, but it is selective. The majors are reshaping their portfolios through disposals, and both strategics and private equity are deploying capital into the right assets. Specified, higher-margin, IP-protected businesses are attracting strong competition; more commoditised processing businesses are still trading, but on cash-flow rather than premium multiples. The most important factor is not market timing but how clearly an owner can evidence the durability and defensibility of the business's earnings.

What makes a food ingredients business worth a premium valuation?

Specification rather than scale. A patented, formulated, clinically-supported or regulatory-approved ingredient that is hard to substitute commands a far higher multiple than a commoditised input, even at the same margin. Proprietary formulations, blue-chip customer relationships, regulatory approvals and a documented switching cost are the attributes that move a business up the valuation ladder — and they should be the centre of how the business is presented to buyers.

Free business valuation & exit readiness assessment

Deal Ascent advises UK family- and founder-owned businesses on sale processes, acquisitions and strategic options across the food, ingredients, consumer and industrial sectors. If you would like a confidential view on how your business would be positioned and valued in the current market, we would be glad to talk.

This article is intended for information purposes only and does not constitute financial, tax or legal advice. Valuation multiples are based on listed peer group consensus estimates as of Q2 2026 and are provided for directional context only. Private company transactions will differ. Specific professional advice should be sought before making any business or financial decisions.